BACKGROUND AND PURPOSE:Telemedicine can disseminate vascular neurology expertise and optimize recombinant tissue plasminogen activator (rt-PA) use for acute ischemic stroke in rural underserved communities. The purpose of this study was to prospectively assess whether telemedicine or telephone was superior for decision-making. METHODS: The study design is a pooled analysis of two identically designed randomized controlled trials conducted in a multistate hub and spoke telestroke network settingwith acute stroke syndrome patients, comparing telemedicine versus telephone-only consultations. From each trial, common data elements were pooled to assess, principally, for correctness of thrombolysis decision-making. Secondary outcomes included rt-PA use rate, 90-day functional outcome, post-thrombolysis intracranial hemorrhage, and data completeness. RESULTS:Two hundred seventy-six pooled patients were evaluated. Correct thrombolysis eligibility decisions were made more often with telemedicine (96% telemedicine, 83% telephone; odds ratio [OR] 4.2; 95% confidence interval [CI] 1.69-10.46; p=0.002). Intravenous rt-PA usage was 26% (29% telemedicine, 24% telephone; OR 1.27; 95% CI 0.71-2.25; p=0.41). Ninety-day outcomes were not different for Barthel Index, modified Rankin Scale, or mortality. There was no difference in post-thrombolysis intracranial hemorrhage (8% telemedicine, 6% telephone; p>0.999). CONCLUSIONS: This pooled analysis supports the hypothesis that stroke telemedicine consultations, compared with telephone-only, result in more accurate decision-making. Together with high rt-PA utilization rate, low post-rt-PA intracranial hemorrhage rate, and acceptable patient outcome, the results confirm that telemedicine is a viable consultative tool for acute stroke. The replication of the hub and spoke network infrastructure supports the generalizability of telemedicine when used in broader settings.
RCT Entities:
BACKGROUND AND PURPOSE: Telemedicine can disseminate vascular neurology expertise and optimize recombinant tissue plasminogen activator (rt-PA) use for acute ischemic stroke in rural underserved communities. The purpose of this study was to prospectively assess whether telemedicine or telephone was superior for decision-making. METHODS: The study design is a pooled analysis of two identically designed randomized controlled trials conducted in a multistate hub and spoke telestroke network setting with acute stroke syndromepatients, comparing telemedicine versus telephone-only consultations. From each trial, common data elements were pooled to assess, principally, for correctness of thrombolysis decision-making. Secondary outcomes included rt-PA use rate, 90-day functional outcome, post-thrombolysis intracranial hemorrhage, and data completeness. RESULTS: Two hundred seventy-six pooled patients were evaluated. Correct thrombolysis eligibility decisions were made more often with telemedicine (96% telemedicine, 83% telephone; odds ratio [OR] 4.2; 95% confidence interval [CI] 1.69-10.46; p=0.002). Intravenous rt-PA usage was 26% (29% telemedicine, 24% telephone; OR 1.27; 95% CI 0.71-2.25; p=0.41). Ninety-day outcomes were not different for Barthel Index, modified Rankin Scale, or mortality. There was no difference in post-thrombolysis intracranial hemorrhage (8% telemedicine, 6% telephone; p>0.999). CONCLUSIONS: This pooled analysis supports the hypothesis that stroke telemedicine consultations, compared with telephone-only, result in more accurate decision-making. Together with high rt-PA utilization rate, low post-rt-PA intracranial hemorrhage rate, and acceptable patient outcome, the results confirm that telemedicine is a viable consultative tool for acute stroke. The replication of the hub and spoke network infrastructure supports the generalizability of telemedicine when used in broader settings.
Authors: Brett C Meyer; Rema Raman; Karin Ernstrom; Gilda M Tafreshi; Branko Huisa; Andrew B Stemer; Thomas M Hemmen Journal: J Stroke Cerebrovasc Dis Date: 2010-09-19 Impact factor: 2.136
Authors: Brett C Meyer; Rema Raman; Thomas Hemmen; Richard Obler; Justin A Zivin; Ramesh Rao; Ronald G Thomas; Patrick D Lyden Journal: Lancet Neurol Date: 2008-09 Impact factor: 44.182
Authors: Sam Wang; Sung Bae Lee; Carol Pardue; Davinder Ramsingh; Jennifer Waller; Hartmut Gross; Fenwick T Nichols; David C Hess; Robert J Adams Journal: Stroke Date: 2003-09-18 Impact factor: 7.914
Authors: S Schwab; B Vatankhah; C Kukla; M Hauchwitz; U Bogdahn; A Fürst; H J Audebert; M Horn Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: René Handschu; Mateusz Scibor; Barbara Willaczek; Martin Nückel; Josef G Heckmann; Dirk Asshoff; Dieter Belohlavek; Frank Erbguth; Stefan Schwab Journal: J Neurol Date: 2008-12-08 Impact factor: 4.849
Authors: E Ray Dorsey; Alistair M Glidden; Melissa R Holloway; Gretchen L Birbeck; Lee H Schwamm Journal: Nat Rev Neurol Date: 2018-04-06 Impact factor: 42.937
Authors: Bart M Demaerschalk; Bentley J Bobrow; Rema Raman; Karin Ernstrom; Joseph M Hoxworth; Ameet C Patel; Terri-Ellen J Kiernan; Maria I Aguilar; Timothy J Ingall; David W Dodick; Brett C Meyer Journal: Stroke Date: 2012-09-13 Impact factor: 7.914
Authors: Mohammad Anadani; Eyad Almallouhi; Amy E Wahlquist; Ellen Debenham; Christine A Holmstedt Journal: Telemed J E Health Date: 2019-02-12 Impact factor: 3.536
Authors: Rashid L Bashshur; Gary W Shannon; Brian R Smith; Dale C Alverson; Nina Antoniotti; William G Barsan; Noura Bashshur; Edward M Brown; Molly J Coye; Charles R Doarn; Stewart Ferguson; Jim Grigsby; Elizabeth A Krupinski; Joseph C Kvedar; Jonathan Linkous; Ronald C Merrell; Thomas Nesbitt; Ronald Poropatich; Karen S Rheuban; Jay H Sanders; Andrew R Watson; Ronald S Weinstein; Peter Yellowlees Journal: Telemed J E Health Date: 2014-06-26 Impact factor: 3.536
Authors: Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens Journal: J Neurol Date: 2012-08-23 Impact factor: 4.849